Grace Science

Grace Science is the developer of NGLY1 small molecule inhibitors for the treatment of various forms of cancer. The company's product GS-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), an AAV9 gene replacement therapy for the treatment of NGLY1 deficiency.